What is Cartalax?
Cartalax is the synthetic tripeptide Ala-Glu-Asp (AED), also studied under the code T-31. Its cartilage focus concerns chondrocytes, the cells that maintain cartilage, and stem cells that can develop cartilage-like features.[1][2][6]
Cartilage depends on cells producing a supportive matrix of collagen and water-binding molecules. AED experiments examine signals involved in making that matrix and changes that occur as the cells age.[1][2]
Purified AED and a cartilage-derived polypeptide complex are different materials. Studies that compare them do not make them interchangeable, even when both are sold within a cartilage-focused product family.[1][6]
What Cartalax is investigated for
Cartalax evidence is grouped by practical use case and oral route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.
Cartilage-cell differentiation
Oral
Cartilage-cell differentiation
Oral
The findings support a cartilage-formation hypothesis; they do not demonstrate joint rebuilding or pain relief in people.[1]
Age-related cartilage-cell changes
Oral
Age-related cartilage-cell changes
Oral
Reduced cell-aging markers are a possible mechanism, not proof that an oral product slows human joint degeneration.[2]
Bone preservation
Oral
Bone preservation
Oral
Animal bone-density findings do not establish fracture prevention or a human osteoporosis treatment.[6]
Evidence snapshot
Overall confidence
Preclinical findings support interest in cartilage maintenance. Benefits for joint pain, function or cartilage rebuilding remain unestablished.[1][2][6]
Overall confidence is a page-level composite, not an average; it weighs evidence quality, route/molecule match, and practical limitations.
Human evidence
Clinical benefits for joint symptoms remain unestablished.[1]
Animal / preclinical
Preclinical findings concern cartilage-cell development, aging and tissue maintenance.[1][2][3][4][5][6]
Mechanism support
AED may influence SOX9 and related signals involved in developing cartilage-producing cells. It can also affect aggrecan and type II collagen, components of cartilage’s supportive matrix.[1]
Forms & administration
Cartalax has oral capsules and lingual drops. Strengths, delivery volumes and amounts are product-specific and need to be considered separately.[18][19]
Dosing & protocols
These ranges are general reference points, not personal dosing instructions.
Safety profile
Cell and rat studies cannot establish a human side-effect profile for Cartalax. Purified AED and cartilage extracts have different compositions and experimental effects.[1][6]
Regulatory status
United States
Cartalax is not an FDA-approved drug name. Availability of a supplement or research preparation does not establish approval for a medical use.[20]
| Route | FDA drug approval | 503A compounding |
|---|---|---|
| Oral | Not Approved Cartalax is not an FDA-approved drug name. Availability of a supplement or research preparation does not establish approval for a medical use.[20] | Not Reviewed Compounding eligibility for this specific preparation has not been confirmed. Drug approval and compounding eligibility are separate questions. |
Oral
FDA drug approval
Not ApprovedCartalax is not an FDA-approved drug name. Availability of a supplement or research preparation does not establish approval for a medical use.[20]
503A compounding
Not ReviewedCompounding eligibility for this specific preparation has not been confirmed. Drug approval and compounding eligibility are separate questions.
International
Medicinal-product authorization outside the United States remains unconfirmed for the named preparation; status depends on the exact product and country.[20]
Sports & competition
WADA S0 prohibits pharmacological substances without governmental approval for human therapeutic use when no later section addresses them. An unapproved peptide preparation is not athlete-cleared.
How it works
AED may influence SOX9 and related signals involved in developing cartilage-producing cells. It can also affect aggrecan and type II collagen, components of cartilage’s supportive matrix.[1]
Its effects on inflammatory and cell-aging signals may help explain interest in preserving cartilage-cell function. These mechanisms remain experimental.[2]
Research gaps & open questions
What the current literature has not yet settled about Cartalax:
Controlled trials need to measure joint pain, walking function and cartilage changes in people with osteoarthritis. Cell-marker changes cannot establish whether patients feel or function better.[1][2]
Absorption studies need to establish how much AED reaches the bloodstream and joint after capsules or drops, allowing laboratory concentrations to be compared with actual human exposure.[16][18]
Independent replication and repeated-use safety studies are needed to establish whether the findings hold beyond the originating research network and whether any benefit persists after a course.[1][2]
Common questions
Has Cartalax been shown to rebuild cartilage in people?
History & discovery
AED/T-31 research spans bone, cartilage and other tissue models. Its cartilage rationale became more specific as investigators examined the signals that direct stem cells toward cartilage formation.[6][1]
An osteoporosis study compared T-31 with a cartilage extract in rats. Different effects of the two materials reinforced the need to distinguish a defined tripeptide from a mixed extract.[6]
Two cell-culture reports examined aging chondrocytes and human stem-cell differentiation. They provided molecular findings, without testing pain, walking ability or cartilage restoration in patients.[2][1]
21 citations
Cartalax research focuses on cartilage formation, cell aging and tissue maintenance. Clinical benefits for joint pain, function or cartilage repair remain unestablished.[1][2][6][15][21][19]
